<DOC>
	<DOCNO>NCT00487435</DOCNO>
	<brief_summary>The purpose study ass long-term safety profile Tapentadol ( CG5503 ) extend release ( ER ) dosages range 100 250 mg twice day treat patient moderate severe chronic pain period 1 year . The study also assess dosage requirement long term ; characterize adverse event tolerability , sleep quality , potential symptom withdrawal ; characterize pain intensity score overall impression change ; characterize patient-related health outcome .</brief_summary>
	<brief_title>An Open-label Extension Study With Flexible Dosing Extended-release ( ER ) Tapentadol ( CG5503 ) Treat Patients With Moderate Severe Chronic Pain</brief_title>
	<detailed_description>All patient complete Phase 3 pivotal trial osteoarthritis ( R331333-PAI-3008 ; KF5503/11 ) low back pain ( R331333-PAI-3011 ; KF5503/23 ) Phase 3 safety trial non-European site ( R331333-PAI-3007 ; KF5503/24 ) allow continue participation program enter trial . The trial consist three period ( screen , open-label treatment period , follow-up ) . In open-label treatment/maintenance period ( 1 year ) , patient safety trial R331333-PAI-3007 ( KF5503/24 ) take open-label Tapentadol ( CG5503 ) extend release ( ER ) continue dosage take without undergo titration . All patient titrate minimum therapeutic dosage Tapentadol ( CG5503 ) extend release ( ER ) 1 week . The low therapeutic dose allow study 100 mg twice daily , maximum upper dosage Tapentadol ( CG5503 ) extend release ( ER ) base 250 mg twice daily . Downward titration ( minimum therapeutic dose 100 mg twice daily ) permit time use decrement without time restriction . Dosages assess schedule ( unscheduled , ) visit adjustment investigator supervision make necessary . Dosage adjustment keep minimum . Intake paracetamol/acetaminophen two 500 mg tablet daily permit titration week , remainder open-label treatment/maintenance period maximum 7 consecutive day 14 30 day . Following Week 4 , visit schedule 4-week interval , Week 52 . The end-of-treatment visit Week 52 include safety efficacy assessment . Patients return site follow-up visit approximately 4 day last dose Tapentadol ( CG5503 ) extend release ( ER ) final safety evaluation completion opioid withdrawal assessment ( clinical opioid withdrawal scale , COWS , subjective opioid withdrawal scale , SOWS ) . Patients experience withdrawal symptom prior follow-up visit may telephone request see sooner . Additionally , research staff site telephone subject approximately 10 14 day last dose Tapentadol ( CG5503 ) extend release ( ER ) inquire adverse event occur since previous visit . Tapentadol ( CG5503 ) extend release ( ER ) : 50 , 100 , 150 , 200 , 250 mg orally , take twice daily ( morning evening ) maximum duration 1 year .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Nonlactating female subject ( Sexually active woman must postmenopausal , surgically sterile , practice effective method birth control [ e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , double barrier method , contraceptive patch , male partner sterilization ] entry throughout trial . Female patient childbearing potential must negative pregnancy test screening . ) Completion expect doubleblind treatment period pivotal Tapentadol ( CG5503 ) Phase 3 trial osteoarthritis ( R331333PAI3008 , KF5503/11 ) low back pain ( R331333PAI3011 , KF5503/23 ) , completion 1year treatment period safety CG5503 Phase 3 trial nonEuropean site ( R331333PAI3007 , KF5503/24 ) Must willing take Tapentadol ( CG5503 ) extend release ( ER ) rescue medication supply duration trial History alcohol and/or drug abuse , lifelong history seizure disorder epilepsy , follow within past year : mild/moderate traumatic brain injury , stroke , transient ischemic attack , brain neoplasm Severe traumatic brain injury within past 15 year Uncontrolled hypertension ( repeat systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 95 mmHg ) Severely impaired renal function Moderately severely impair hepatic function Patients take neuroleptic , monoamine oxidase inhibitor , tricyclic antidepressant within 14 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>CG5503</keyword>
	<keyword>Tapentadol</keyword>
	<keyword>chronic non-malignant pain</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>low back pain</keyword>
	<keyword>analgesic</keyword>
	<keyword>opioid</keyword>
</DOC>